Plant Name: Curcuma aromatica
Taxonomic Information:
Plant ID: NPO25209
Plant Latin Name: Curcuma aromatica
Taxonomy Genus: Curcuma
Taxonomy Family: Zingiberaceae
Plant External Links:
NCBI TaxonomyDB:
136209
Plant-of-the-World-Online:
796426-1
Used in Medicines:
Country/Region:
Thailand; China; IndiaTraditional Medicine System:
Indian Folk; TCM; Unani; Ayurveda; SiddhaGeographical Distribution:
Bangladesh; Myanmar; Nepal; India; Vietnam; China; Sri Lanka; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; TSHR; | |
| CACNA1C; | |
| PTGES; HSD17B3; ALDH1A1; | |
| MAP3K7; MAP2K7; MAPK1; MAP2K1; | |
| CA2; | |
| AR; | |
| ALOX5; MAOA; | |
| RELA; | |
| SERPINA6; F3; SHBG; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP19A1; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | P37058 | CHEMBL4234 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 | O43318 | CHEMBL5776 |
| Protein Kinase | MAP2K7 | Dual specificity mitogen-activated protein kinase kinase 7 | O14733 | CHEMBL3530 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
| Voltage-gated calcium channel | CACNA1C | Voltage-gated L-type calcium channel alpha-1C subunit | Q13936 | CHEMBL1940 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005497; androgen binding | 3.225E-09 | 7.023E-05 | ALDH1A1, AR, SHBG |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 3.644E-07 | 3.967E-03 | MAP2K1, MAP2K7, MAPK1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 3.787E-08 | 1.952E-06 | MAP2K1, MAPK1, MAP2K7, MAP3K7, RELA |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 4.168E-08 | 1.952E-06 | MAP2K1, MAPK1, MAP2K7, MAP3K7, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.022E-08 | 1.952E-06 | MAP2K1, MAPK1, MAP2K7, MAP3K7, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 9.563E-08 | 2.716E-06 | MAP2K1, MAPK1, CACNA1C, MAP2K7, MAP3K7, RELA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.498E-08 | 1.952E-06 | MAP2K1, MAOA, ALOX5, MAPK1, CACNA1C |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 1.253E-07 | 2.965E-06 | MAP2K1, MAPK1, MAP2K7, MAP3K7, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.628E-07 | 1.953E-05 | MAP2K1, MAPK1, CACNA1C, RELA, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.349E-06 | 2.328E-05 | AR, MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.475E-06 | 2.328E-05 | MAP2K1, MAPK1, CACNA1C, MAP2K7 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 4.167E-06 | 5.752E-05 | ALOX5, MAPK1, MAP3K7, RELA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 4.456E-06 | 5.752E-05 | MAP2K1, MAPK1, MAP2K7, RELA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.981E-05 | 2.088E-04 | MAP2K1, MAPK1, MAP2K7, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.059E-05 | 2.088E-04 | MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 3.503E-05 | 2.926E-04 | MAP2K1, MAPK1, MAP2K7 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.203E-05 | 2.842E-04 | MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04720 | Long-term potentiation | 3.203E-05 | 2.842E-04 | MAP2K1, MAPK1, CACNA1C |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.059E-05 | 2.088E-04 | MAPK1, MAP3K7, RELA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.159E-05 | 2.931E-04 | MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 4.335E-05 | 2.931E-04 | MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.335E-05 | 2.931E-04 | MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.142E-04 | 7.051E-04 | MAPK1, F3, RELA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 4.335E-05 | 2.931E-04 | MAPK1, MAP3K7, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 7.326E-05 | 4.728E-04 | MAP2K1, MAPK1, MAP2K7 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.511E-04 | 8.583E-04 | MAP2K1, MAPK1, CACNA1C |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.211E-04 | 7.163E-04 | MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04270 | Vascular smooth muscle contraction | 1.903E-04 | 1.001E-03 | MAP2K1, MAPK1, CACNA1C |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 2.047E-04 | 1.038E-03 | AR, MAP2K1, MAPK1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.996E-04 | 1.418E-03 | MAP2K1, MAPK1, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.903E-04 | 1.001E-03 | MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.679E-04 | 1.954E-03 | AR, MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.389E-04 | 1.517E-03 | MAP2K1, MAPK1, RELA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 4.271E-04 | 1.838E-03 | MAP2K1, MAPK1, CACNA1C |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 5.022E-04 | 1.981E-03 | MAP2K1, MAPK1, CACNA1C |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.523E-04 | 2.671E-03 | MAOA, ALOX5, ALDH1A1, HSD17B3, CYP19A1, PTGES |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 6.147E-04 | 2.359E-03 | MAP2K1, MAOA, MAPK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 6.980E-04 | 2.541E-03 | MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.730E-04 | 3.023E-03 | MAP2K7, MAP3K7, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.222E-03 | 3.774E-03 | MAP2K1, MAPK1, RELA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.887E-03 | 8.052E-03 | MAP2K1, MAPK1, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.277E-03 | 3.858E-03 | MAP2K1, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.513E-03 | 4.268E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.102E-03 | 3.478E-03 | MAP2K1, MAPK1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04730 | Long-term depression | 1.465E-03 | 4.244E-03 | MAP2K1, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 3.849E-03 | 8.052E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.716E-03 | 4.513E-03 | MAP2K1, MAPK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 3.474E-03 | 7.590E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.563E-03 | 4.268E-03 | MAP2K1, MAPK1 |
| 09150 Organismal Systems | 09159 Environmental adaptation | hsa04713 | Circadian entrainment | 3.622E-03 | 7.793E-03 | MAPK1, CACNA1C |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.858E-04 | 2.541E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 9.397E-04 | 3.177E-03 | MAPK1, CACNA1C |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.019E-03 | 3.290E-03 | ALOX5, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.926E-03 | 8.052E-03 | MAP2K1, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 4.004E-03 | 8.052E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.769E-03 | 4.539E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.043E-03 | 4.918E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 1.822E-03 | 4.539E-03 | MAOA, CACNA1C |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 4.083E-03 | 8.052E-03 | MAP2K1, MAPK1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 3.118E-03 | 7.027E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.822E-03 | 4.539E-03 | MAP2K1, MAPK1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 3.474E-03 | 7.590E-03 | MAP3K7, RELA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 5.169E-03 | 9.919E-03 | MAPK1, CACNA1C |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 9.791E-04 | 3.233E-03 | MAOA, RELA |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 3.419E-04 | 1.517E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 2.980E-03 | 6.825E-03 | MAPK1, RELA |
| 09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 4.083E-03 | 8.052E-03 | MAPK1, CACNA1C |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 2.959E-04 | 1.418E-03 | MAP2K1, MAPK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 4.323E-03 | 8.409E-03 | MAPK1, RELA |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.217E-03 | 5.247E-03 | MAPK1, MAP3K7 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.369E-03 | 4.051E-03 | HSD17B3, CYP19A1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 1.716E-03 | 4.513E-03 | MAPK1, RELA |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05020 | Prion diseases | 4.993E-04 | 1.981E-03 | MAP2K1, MAPK1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.563E-03 | 4.268E-03 | ALOX5, PTGES |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 2.277E-03 | 5.300E-03 | MAPK1, RELA |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 1.987E-03 | 4.865E-03 | MAP3K7, RELA |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; MAPK1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | CACNA1C; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | CACNA1C; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGES; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | CACNA1C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; SERPINA6; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| C00-D49: Neoplasms | Mantle cell lymphoma | C81-C86, C85.7, C90.0, C91-C95 | MAP3K7; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
